saxagliptin protects early nephropathy of type 2 diabetes by increasing SDF-1a level: A mechanistic study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17014233

Enrollment

Unknown

Registered

2017-12-30

Start date

2017-12-30

Completion date

Unknown

Last updated

2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy

Interventions

saxagliptin group:saxagliptin

Acarbose group:acarbose

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) have been diagnosed as type 2 diabetes; (2) be at least 18 years old; (3) microalbuminuria ACR 30-300ug/gCr; (4) HbA1c 7.5%~10.0%.

Exclusion criteria

Exclusion criteria: (1) type 1 diabetes; (2) have used any one or more of the following medecation: GLP-1 analogue, DPP-4 inhibitors, a-glucosidase inhibitors, or ABBs analogues; (3) have a history of acute or chronic pancreatitis; (4) congestive heart failure; (5) acute cardiovascular and cerebrovascular diseases; (6) pregnancy or lactation.

Design outcomes

Primary

Measure	Time frame
ACR;SDF-1a;	—

Secondary

Measure	Time frame
8-OHdG;nephrin;desmin;	—

Countries

China

Contacts

Public ContactJuanjuan Guo

Tianjin Medical University Metabolic Diseases Hospital

guojuanjuan2005@163.com+86 19320453941

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026